Cart
sales@molnova.com
Senexin-A
CAS No. 1366002-50-7
Senexin-A( Senexin A )
Catalog No. M11512 CAS No. 1366002-50-7
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 67 | In Stock |
|
| 10MG | 96 | In Stock |
|
| 25MG | 187 | In Stock |
|
| 50MG | 333 | In Stock |
|
| 100MG | 475 | In Stock |
|
| 200MG | 644 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSenexin-A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
DescriptionA selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively; inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells; suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts and reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.
-
In Vitro——
-
In Vivo——
-
SynonymsSenexin A
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1366002-50-7
-
Formula Weight274.32
-
Molecular FormulaC17H14N4
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥100 mg/mL
-
SMILESN#CC1=CC2=C(NCCC3=CC=CC=C3)N=CN=C2C=C1
-
Chemical Name6-Quinazolinecarbonitrile, 4-[(2-phenylethyl)amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Porter DC, et al. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13799-804.
2. McDermott MS, et al. Oncotarget. 2017 Feb 21;8(8):12558-12575.
molnova catalog
related products
-
CDK7 and 9 inhibitor...
A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.
-
MSC-2530818
MSC-2530818 (MSC 2530818, MSC2530818) is a potent, selective, and orally bioavailable CDK8 inhibitor with IC50 of 2.6 nM.
-
FMF-04-159-2
FMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18).
